The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
TP53 mutation in colorectal cancer
Open accessAbstract
Approximately half of all colorectal cancers show p53 (TP53) gene mutations, with higher frequencies observed in distal colon and rectal tumors and lower frequencies in proximal tumors and those with the microsatellite instability or methylator phenotypes. Alterations to this gene appear to have little or no prognostic value for colorectal cancer patients treated by surgery alone, but are associated with worse survival for patients treated with chemotherapy. There is some evidence that different p53 mutations are associated with different clinical features including prognosis and response to therapy, although further large studies are required to confirm this. Several in vitro, animal and clinical studies have shown that normal p53 is required for the response of colorectal cancers to 5-fluorouracil-based chemotherapy. This should be confirmed by additional retrospective cohort studies and by the incorporation of P53 status in ongoing and future clinical trials. The evaluation of p53 overexpression, using a standardized immunohistochemical (IHC) procedure, could be a clinically useful marker for the identification of colorectal cancer patients likely to benefit from the standard chemotherapy regime currently used for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“These clinical results are in agreement with in vitro and animal studies that show a requirement for normal p53 in order for colorectal tumor cells to respond to 5FU [Bunz et al., 1999].”
Resultp53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,003
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
Baas, I. O., Mulder, J. R., Offerhaus, G. J. A., Vogelstein, B., & Hamilton, S. R. (1994) · The Journal of Pathology · doi:10.1002/path.1711720104 · Cited by 505
A simple p53 functional assay for screening cell lines, blood, and tumors.
Flaman, J. M., Frebourg, T., Moreau, V, Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 454
Ahnen, D. J., Feigl, P., Quan, G., Fenoglio‐Preiser, C. M., Lovato, L., Bunn, P. A., Stemmerman, G. N., Wells, J. D., Macdonald, J. S., & Meyskens, F. L. (1998) · PubMed · Cited by 338
MULTIPLE GENETIC ALTERATIONS IN DISTAL AND PROXIMAL COLORECTAL CANCER
Delattre, O., Law, D. J., Remvikos, Y., Sastre, X., Feinberg, A. P., Olschwang, S., Melot, T., Salmon, R. J., Validire, P., & Thomas, G. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90537-0 · Cited by 302
Soussi, T., Dehouche, K., & B�roud, C. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200001)15:1<105::aid-humu19>3.0.co;2-g · Cited by 271
Cited by
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
“compared to tumors lacking p53 mutations (Iacopetta, 2003; Lai et al., 2000; Powell et al., 2000; Skaug et al., Design of siRNAs Specific for Murine p53, p63, and p73 2000).”
SIGNALING PATHWAYS IN INTESTINAL DEVELOPMENT AND CANCER
Sancho, E., Batlle, E., & Clevers, H. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.092805 · Cited by 532
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer
Carethers, J. M., & Jung, B. H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.047 · Cited by 483
“Chromosome 18q21 LOH, the location of SMAD2 and SMAD4, is selected for in 80% of stage IV CRC patients [107,108].”
Backgroundp53: 25 years after its discovery
Hofseth, L. J., Hussain, S. P., & Harris, C. C. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.009 · Cited by 431
Russo, A., Bazan, V., Iacopetta, B., Kerr, D., Soussi, T., & Gebbia, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.471 · Cited by 416
Self-citationp53 mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation
Li, X.-L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.84 · Cited by 367
Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview
Wang, L.-H., Wu, C.-F., Rajasekaran, N., & Shin, Y. K. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495956 · Cited by 334
Kondo, J., Endo, H., Okuyama, H., Ishikawa, O., Iishi, H., Tsujii, M., Ohue, M., & Inoue, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015938108 · Cited by 322
“About 50% of colorectal cancers have TP53 mutations (20, 21).”
BackgroundVogt, M., Munding, J., Grüner, M., Liffers, S.-T., Verdoodt, B., Hauk, J., Steinstraesser, L., Tannapfel, A., & Hermeking, H. (2011) · Virchows Archiv · doi:10.1007/s00428-010-1030-5 · Cited by 309
Kotler, E., Shani, O., Goldfeld, G., Lotan-Pompan, M., Tarcic, O., Gershoni, A., Hopf, T. A., Marks, D. S., Oren, M., & Segal, E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.012 · Cited by 285
Colorectal cancer: genetics of development and metastasis
Takayama, T., Miyanishi, K., Hayashi, T., Sato, Y., & Niitsu, Y. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1801-6 · Cited by 265
TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression
Wang, S., Zhang, Y., Huang, J., Wong, C. C., Zhai, J., Li, C., Wei, G., Zhao, L., Wang, G., Wei, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3614 · Cited by 104
Zhuang, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08108-9 · Cited by 54
Alzoubi, S., Brody, L., Rahman, S., Mahul-Mellier, A.-L., Mercado, N., Ito, K., El-Bahrawy, M., Silver, A., Boobis, A., Bell, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9887 · Cited by 37
Metadata
- Authors
- Iacopetta, B.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2003-02-27
- Volume
- 21
- Issue
- 3
- Pages
- 271-276
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W2088010622
- Cited by
- 345
- References
- 34
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.